Bio-Gene Technology Ltd (AU:BGT) — Stock Price
Bio-Gene Technology Ltd (AU:BGT) is currently trading at AU$0.02 AUD, down 4.35% today. Over the past 52 weeks, shares have ranged between AU$0.02 and AU$0.04. This page tracks Bio-Gene Technology Ltd's live share price on the AU exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Bio-Gene Technology Ltd stock valuation.
Bio-Gene Technology Ltd (BGT) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Bio-Gene Technology Ltd's daily closing share price and trading volume on the AU exchange over the past year, giving a clear view of recent price momentum and liquidity.
Bio-Gene Technology Ltd Income Statement — Revenue, Profit & Earnings by Year
Bio-Gene Technology Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | AU$425.07K | AU$18.32K | AU$149.23K | AU$445.73K | AU$62.61K |
| Cost of Revenue | AU$245.78K | AU$319.77K | AU$313.27K | AU$267.14K | AU$173.20K |
| Gross Profit | AU$-245.78K | AU$-301.45K | AU$-164.04K | AU$178.59K | AU$-110.59K |
| Research & Development | AU$1.38 Million | AU$1.07 Million | AU$1.98 Million | AU$1.90 Million | AU$1.68 Million |
| SG&A | AU$884.56K | AU$1.42 Million | AU$1.18 Million | AU$802.49K | AU$567.09K |
| Total Operating Expenses | AU$2.82 Million | AU$2.76 Million | AU$3.46 Million | AU$3.59 Million | AU$2.86 Million |
| Operating Income | AU$-3.07 Million | AU$-3.06 Million | AU$-3.63 Million | AU$-3.41 Million | AU$-2.60 Million |
| EBITDA | AU$-2.58 Million | AU$-2.97 Million | AU$-3.14 Million | AU$-2.92 Million | AU$-2.85 Million |
| EBIT | AU$-2.62 Million | AU$-3.01 Million | AU$-3.18 Million | AU$-2.97 Million | AU$-2.91 Million |
| Interest Expense | — | — | — | AU$52.86K | AU$337.00 |
| Income Before Tax | AU$-2.58 Million | AU$-3.01 Million | AU$-3.10 Million | AU$-2.91 Million | AU$-2.40 Million |
| Income Tax Expense | AU$-385.63K | AU$-604.19K | AU$-445.85K | AU$-434.05K | AU$-510.51K |
| Net Income | AU$-2.58 Million | AU$-2.41 Million | AU$-3.10 Million | AU$-2.91 Million | AU$-2.40 Million |
Bio-Gene Technology Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Bio-Gene Technology Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | AU$2.15 Million | AU$3.16 Million | AU$3.84 Million | AU$7.30 Million | AU$5.00 Million |
| Total Current Assets | AU$1.97 Million | AU$2.94 Million | AU$3.58 Million | AU$7.00 Million | AU$4.66 Million |
| Cash & Equivalents | — | — | — | — | AU$3.93 Million |
| Short-term Investments | AU$500.00K | AU$1.50 Million | — | AU$74.20K | — |
| Net Receivables | AU$472.42K | AU$523.96K | AU$445.55K | AU$438.17K | AU$523.75K |
| Inventory | — | — | AU$70.19K | AU$148.84K | AU$132.87K |
| Property, Plant & Equipment | AU$13.35K | AU$19.01K | AU$14.64K | AU$22.99K | AU$22.73K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | AU$522.98K | AU$368.45K | AU$613.88K | AU$1.03 Million | AU$754.57K |
| Total Current Liabilities | AU$510.13K | AU$345.93K | AU$573.87K | AU$1.01 Million | AU$592.71K |
| Long-term Debt | — | — | AU$0.00 | AU$0.00 | AU$150.00K |
| Net Debt | AU$-1.14 Million | AU$-2.21 Million | AU$-2.99 Million | AU$-6.34 Million | AU$-3.93 Million |
| Total Stockholder Equity | AU$1.63 Million | AU$2.79 Million | AU$3.22 Million | AU$6.27 Million | AU$4.25 Million |
| Retained Earnings | AU$-22.03 Million | AU$-19.64 Million | AU$-17.43 Million | AU$-14.50 Million | AU$-11.68 Million |
Bio-Gene Technology Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Bio-Gene Technology Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | AU$-2.54 Million | AU$-2.75 Million | AU$-3.28 Million | AU$43.52K | AU$-1.83 Million |
| Capital Expenditures | AU$0.00 | AU$5.70K | AU$0.00 | AU$6.84K | AU$3.03K |
| Free Cash Flow | AU$-2.54 Million | AU$-2.76 Million | AU$-3.28 Million | AU$36.67K | AU$-1.83 Million |
| Investing Cash Flow | AU$0.00 | AU$-5.70K | AU$0.00 | AU$-6.84K | AU$-3.03K |
| Financing Cash Flow | AU$1.47 Million | AU$1.98 Million | AU$-75.00K | AU$4.41 Million | AU$239.88K |
| Dividends Paid | — | — | — | AU$75.00K | AU$11.66K |
| Stock-Based Compensation | — | — | AU$48.66K | AU$453.01K | AU$367.53K |
| Depreciation | AU$41.93K | AU$38.38K | AU$45.30K | AU$43.52K | AU$54.22K |
| Change in Cash | AU$-1.07 Million | AU$-780.97K | AU$-3.35 Million | AU$2.41 Million | AU$-1.59 Million |
Bio-Gene Technology Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Bio-Gene Technology Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 25, 2026 | — | — | — |
| Aug 25, 2025 | -0.01 | 0.00 | — |
| Feb 27, 2025 | -0.01 | 0.00 | — |
| Oct 31, 2024 | — | — | — |
| Feb 23, 2023 | -0.01 | — | — |
| Aug 15, 2022 | -0.01 | — | — |
| Feb 16, 2022 | -0.01 | 0.00 | — |
| Aug 26, 2021 | -0.01 | — | — |